A detailed history of Aqr Capital Management LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 8,842 shares of BEAM stock, worth $235,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,842
Previous 9,011 1.88%
Holding current value
$235,108
Previous $211,000 2.37%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$22.57 - $33.14 $3,814 - $5,600
-169 Reduced 1.88%
8,842 $216,000
Q2 2024

Aug 14, 2024

BUY
$21.22 - $32.66 $52,774 - $81,225
2,487 Added 38.12%
9,011 $211,000
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $153,053 - $294,036
6,524 New
6,524 $215,000
Q4 2022

Feb 14, 2023

SELL
$36.73 - $51.6 $1,542 - $2,167
-42 Reduced 0.44%
9,599 $375,000
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $383,615 - $677,858
9,641 New
9,641 $459,000
Q1 2022

May 16, 2022

SELL
$53.73 - $82.16 $398,891 - $609,955
-7,424 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $1.04 Million - $1.52 Million
-15,304 Reduced 67.34%
7,424 $592,000
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $356,716 - $564,860
4,228 Added 22.85%
22,728 $1.98 Million
Q2 2021

Aug 16, 2021

BUY
$64.12 - $128.71 $511,613 - $1.03 Million
7,979 Added 75.84%
18,500 $2.38 Million
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $151,256 - $256,231
2,122 Added 25.26%
10,521 $842,000
Q4 2020

Feb 16, 2021

BUY
$22.24 - $95.63 $186,793 - $803,196
8,399 New
8,399 $686,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.87B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.